Graduate School of Pharmaceutical Sciences, Hokkaido University
Laboratory for Bioanalysis and Molecular Imaging
Publications

Research Achievements

Original Article

  1. Nakajima K*, Miyazaki F*, Terada K, Takakura H, Suzuki M, Ogawa M. Comparison of low-molecular-weight ligand and whole antibody in prostate-specific membrane antigen targeted near-infrared photoimmunotherapy. Int J Pharm 2021, 609, 121135. *Contributed equally. PMID 34571072
  2. Suzuki M, Katayama T, Suzuki C, Nakajima K, Magata Y, Ogawa M. Uptake of nicotinic acetylcholine receptor imaging agent is reduced in the pro-inflammatory macrophage. Nucl Med Biol 2021, 102-103, 45-55. PMID 34619460
  3. Kato T, Okada R, Goto Y, Furusawa A, Inagaki F, Wakiyama H, Furumoto H, Daar D, Turkbey B, Choyke PL, Takakura H, Inanami O, Ogawa M, Kobayashi H. Electron Donors Rather Than Reactive Oxygen Species Needed for Therapeutic Photochemical Reaction of Near-Infrared Photoimmunotherapy. ACS Pharmacol Transl Sci 2021, 4 (5), 1689-1701. PMID 34661083
  4. Ogawa M, Takakura H. Photoimmunotherapy: A new cancer treatment using photochemical reactions. Bioorg Med Chem 2021, 43, 116274. PMID 34139484
  5. Matsuoka K, Obata H, Nagatsu K, Kojima M, Yoshino T, Ogawa M, Matsunaga S. Transition-metal-free nucleophilic 211At-astatination of spirocyclic aryliodonium ylides. Org Biomol Chem 2021, 19 (25), 5525-5528. PMID 34124736
  6. Sato Y, Yamaguchi K, Ogawa M, Takekuma Y, Sugawara M. An imaging approach for determining the mechanism of enhancement of intestinal absorption of an L-theanine supplement. PLoS One 2021, 16 (6), e0253066. PMID 34115818
  7. Obata H, Tsuji AB, Sudo H, Sugyo A, Minegishi K, Nagatsu K, Ogawa M, Zhang MR. In Vitro Evaluation of No-carrier-added Radiolabeled Cisplatin ([189, 191Pt]cisplatin) Emitting Auger Electrons. Int J Mol Sci 2021, 22, 4622. PMID 33924843
  8. Obata H, Minegishi K, Nagatsu K, Ogawa M, Zhang MR. Synthesis of no-carrier-added [188, 189, 191Pt]cisplatin from a cyclotron produced 188, 189, 191PtCl42-) complex. Sci Rep 2021, 11, 8140. PMID 33854142
  9. Takakura H, Goto Y, Kitamura A, Yoshihara T, Tobita S, Kinjo M, Ogawa M. Analysis of the triplet-state kinetics of a photosensitizer for photoimmunotherapy by fluorescence correlation spectroscopy. J Photochem Photobiol A: Chem 2021, 408, 113094.
  10. Hirata H, Kuwatani M, Nakajima K, Kodama Y, Yoshikawa Y, Ogawa M, Sakamoto N. Near-infrared photoimmunotherapy (NIR-PIT) on cholangiocarcinoma using a novel catheter device with light emitting diodes. Cancer Sci 2021. 112, 828-838. PMID 33345417
  11. Nakajima K, Ogawa M. Phototoxicity in near-infrared photoimmunotherapy is influenced by the subcellular localization of antibody-IR700. Photodiagnosis Photodyn Ther 2020, 31 , 101926. PMID 32717450
  12. Nishimoto Y, Nishio M, Nagashima S, Nakajima K, Ohira T, Nakai S, Nakase I, Higashikawa K, Kuge Y, Matsumoto A, Ogawa M, Kojima C. Association of Hydrophobic Carboxyl-Terminal Dendrimers with Lymph Node-Resident Lymphocytes. Polymers 2020, 12 (7), 1474. PMID 32630042
  13. Kobayashi M, Harada M, Takakura H, Ando K, Goto Y, Takao T, Ogawa M, Taketsugu T. Theoretical and Experimental Studies on the Near-Infrared Photoreaction Mechanism of a Silicon Phthalocyanine Photoimmunotherapy Dye: Photoinduced Hydrolysis by Radical Anion Generation. Chempluschem 2020, 85, 1-6. PMID 32449613 (Cover Profile:PMID 32830450)
  14. Sano M, Hirakawa S, Suzuki M, Sakabe J, Ogawa M, Yamamoto S, Hiraide T, Sasaki T, Yamamoto N, Inuzuka K, Tanaka H, Saito T, Sugisawa R, Katahashi K, Yata T, Kayama T, Urano T, Tokura Y, Sato K, Setou M, Takeuchi H, Konno H, Unno N. Potential Role of Transforming Growth Factor-Beta 1/Smad Signaling in Secondary Lymphedema After Cancer Surgery. Cancer Sci 2020, 111 (7), 2620-2634. PMID 32412154
  15. Kono Y, Yokoyama K, Suzuki M, Takakura H, Ogawa M. Surface modification of liposomes using IR700 enables efficient controlled contents release triggered by near-IR light. Bio Pharm Bull 2020, 43 (4), 736-741. PMID 32238716
  16. Tomita M, Suzuki M, Kono Y, Nakajima K, Matsuda T, Kuge Y, Ogawa M. Influence on [18F]FDG uptake by cancer cells after anti PD-1 therapy in an enforced-immune activated mouse tumor. EJNMMI Res 2020, 10 (1), 24. PMID 32189078
  17. Nishimoto Y, Nagashima S, Nakajima K, Ohira T, Sato T, Izawa T, Yamate J, Higashikawa K, Kuge Y, Ogawa M, Kojima C. Carboxyl-, sulfonyl-, and phosphate-terminal dendrimers as a nanoplatform with lymph node targeting. Int J Pharm 2020, 576, 119021. PMID 31917298
  18. Inubushi M, Shibahara M, Takahashi Y, Ogawa M, Kiyono Y. From the Respective Expert Viewpoints of the ANM Specialty Editors. Ann Nucl Med 2019, 33 (12), 877-889. PMID 31745811
  19. Narita Y, Shimizu K, Ikemoto K, Uchino R, Kosugi M, Maess MB, Magata Y, Oku N, Ogawa M. Macrophage-targeted, enzyme-triggered fluorescence switch-on system for detection of embolism-vulnerable atherosclerotic plaques. J Control Release 2019 . [Epub ahead of print] PMID 30936020
  20. Shimizu Y*, Motomura A*, Takakura H, Tamaki N, Kuge Y, Ogawa M. Accumulation of hypoxia imaging probe "[18F]FMISO" in macrophages depends on macrophage polarization in addition to hypoxic state. Ann Nucl Med 2019, 33 (5), 362-367. *equally contributed. PMID 30694443
  21. Sato K, Ando K, Okuyama S, Moriguchi S, Ogura T, Totoki S, Hanaoka H, Nagaya T, Kokawa R, Takakura H, Nishimura M, Hasegawa Y, Choyke PL, Ogawa M, Kobayashi H. Photoinduced Ligand Release from a Silicon Phthalocyanine Dye Conjugated with Monoclonal Antibodies: A Mechanism of Cancer Cell Cytotoxicity after Near-Infrared Photoimmunotherapy. ACS Cent Sci 2018, 4 (11), 1559-1569. PMID 30555909
  22. Tomita M, Yasui H, Higashikawa K, Nakajima K, Takakura H, Shiga T, Kuge Y, Ogawa M. Anti PD-1 treatment increases [18F]FDG uptake by cancer cells in a mouse B16F10 melanoma model. EJNMMI Research 2018, 8, 82.
  23. Sugita T, Kondo Y, Ishino S, Mori I, Horiguchi T, Ogawa M, Magata Y. Evaluation of drug effects on cerebral blood flow and glucose uptake in un-anesthetized and un-stimulated rats: application of free-moving apparatus enabling to keep rats free during PET/SPECT tracer injection and uptake. Nucl Med Commun 2018, 39 (8), 753-760.
  24. Nakajima K, Takakura H, Shimizu Y, Ogawa M. Changes in plasma membrane damage inducing cell death after treatment with near-infrared photoimmunotherapy. Cancer Sci 2018 109 (9) 2889-2896.
  25. Shimizu Y, Zhao S, Yasui H, Nishijima KI, Matsumoto H, Shiga T, Tamaki N, Ogawa M, Kuge Y. A Novel PET Probe "[18F]DiFA" Accumulates in Hypoxic Region via Glutathione Conjugation Following Reductive Metabolism. Mol Imaging Biol 2018 . [Epub ahead of print]
  26. Nakajima K, Kimura T, Takakura H, Yoshikawa Y, Kameda A, Shindo T, Sato K, Kobayashi H, Ogawa M. Implantable wireless powered light emitting diode (LED) for near-infrared photoimmunotherapy: device development and experimental assessment in vitro and in vivo. Oncotarget 2018, 9 (28), 20048-20057.
  27. Ogawa M, Takakura H. In Vivo Molecular Imaging for Biomedical Analysis and Therapies. Anal Sci 2018, 34 (3), 273-281.
  28. Shimizu Y, Hanzawa H, Zhao Y, Fukura S, Nishijima K. I, Sakamoto T, Zhao S, Tamaki N, Ogawa M, Kuge Y. Immunoglobulin G (IgG)-Based Imaging Probe Accumulates in M1 Macrophage-Infiltrated Atherosclerotic Plaques Independent of IgG Target Molecule Expression. Mol Imaging Biol 2017, 19 (4), 531-539.
  29. Ogawa M, Tomita Y, Nakamura Y, Lee M. J, Lee S, Tomita S, Nagaya T, Sato K, Yamauchi T, Iwai H, Kumar A, Haystead T, Shroff H, Choyke PL, Trepel JB, Kobayashi H. Immunogenic cancer cell death selectively induced by near infrared photoimmunotherapy initiates host tumor immunity. Oncotarget 2017, 8 (6), 10425-10436.
  30. Saito K, Iioka H, Kojima C, Ogawa M, Kondo E. Peptide-based tumor inhibitor encoding mitochondrial p14(ARF) is highly efficacious to diverse tumors. Cancer Sci 2016, 107 (9), 1290-1301.
  31. Kobayashi H, Choyke P. L, Ogawa M. Monoclonal antibody-based optical molecular imaging probes; considerations and caveats in chemistry biology and pharmacology. Curr Opin Chem Biol 2016, 33, 32-38.
  32. Sakai T, Saito Y, Takashima M, Ogawa M, Magata Y. Development of radioiodinated lipophilic cationic compounds for myocardial imaging. Nucl Med Biol 2015, 42 (5), 482-487.
  33. Ogawa M, Uchino R, Kawai A, Kosugi M, Magata Y. PEG modification on (111)In-labeled phosphatidyl serine liposomes for imaging of atherosclerotic plaques. Nucl Med Biol 2015, 42 (3), 299-304.
  34. Niki Y, Ogawa M, Makiura R, Magata Y, Kojima C. Optimization of dendrimer structure for sentinel lymph node imaging: Effects of generation and terminal group. Nanomedicine 2015, 11 (8), 2119-2127.
  35. Hatano K, Sekimata K, Yamada T, Abe J, Ito K, Ogawa M, Magata Y, Toyohara J, Ishiwata K, Biggio G, Serra M, Laquintana V, Denora N, Latrofa A, Trapani G, Liso G, Suzuki H, Sawada M, Nomura M, Toyama H. Radiosynthesis and in vivo evaluation of two imidazopyridineacetamides, [(11)C]CB184 and [(11)C]CB190, as a PET tracer for 18 kDa translocator protein: direct comparison with [(11)C](R)-PK11195. Ann Nucl Med 2015, 29 (4), 325-335.
  36. Asanuma D, Sakabe M, Kamiya M, Yamamoto K, Hiratake J, Ogawa M, Kosaka N, Choyke PL, Nagano T, Kobayashi H, Urano Y. Sensitive beta-galactosidase-targeting fluorescence probe for visualizing small peritoneal metastatic tumours in vivo. Nat Commun 2015, 6, 6463.
  37. Zhu HJ, Ogawa M, Magata Y, Hirata M, Ohmomo Y, Sakahara H. Relationship between uptake of a radioiodinated quinazoline derivative and radiosensitivity in non-small cell lung cancer. Am J Nucl Med Mol Imaging 2014, 4 (4), 293-302.
  38. Sano M, Sasaki T, Hirakawa S, Sakabe J, Ogawa M, Baba S, Zaima N, Tanaka H, Inuzuka K, Yamamoto N, Setou M, Sato K, Konno H, Unno N. Lymphangiogenesis and angiogenesis in abdominal aortic aneurysm. PLoS One 2014, 9 (3), e89830.
  39. Sano K, Iwamiya Y, Kurosaki T, Ogawa M, Magata Y, Sasaki H, Ohshima T, Maeda M, Mukai T. Radiolabeled gamma-polyglutamic acid complex as a nano-platform for sentinel lymph node imaging. J Control Release 2014, 194C, 310-315.
  40. Ogawa M, Umeda I. O, Kosugi M, Kawai A, Hamaya Y, Takashima M, Yin H, Kudoh T, Seno M, Magata Y. Development of 111In-labeled liposomes for vulnerable atherosclerotic plaque imaging. J Nucl Med 2014, 55 (1), 115-120.
  41. Longmire MR, Ogawa M, Choyke PL, Kobayashi H. Dendrimers as high relaxivity MR contrast agents. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2014, 6 (2), 155-162.
  42. Kojima C, Niki Y, Ogawa M, Magata Y. Prolonged local retention of subcutaneously injected polymers monitored by noninvasive SPECT imaging. Int J Pharm 2014, 476 (1-2), 164-168.
  43. Iwaki S, Hokamura K, Ogawa M, Takehara Y, Muramatsu Y, Yamane T, Hirabayashi K, Morimoto Y, Hagisawa K, Nakahara K, Mineno T, Terai T, Komatsu T, Ueno T, Tamura K, Adachi Y, Hirata Y, Arita M, Arai H, Umemura K, Nagano T, Hanaoka K. A design strategy for small molecule-based targeted MRI contrast agents: their application for detection of atherosclerotic plaques. Org Biomol Chem 2014, 12 (43), 8611-8618.
  44. Ishino S, Ogawa M, Mori I, Nishimura S, Ikeda S, Sugita T, Oikawa T, Horiguchi T, Magata Y. F-FDG PET and intravascular ultrasonography (IVUS) images compared with histology of atherosclerotic plaques: F-FDG accumulates in foamy macrophages. Eur J Nucl Med Mol Imaging 2014, 41 (4), 624-633.
  45. Satomi T, Ogawa M, Mori I, Ishino S, Kubo K, Magata Y, Nishimoto T. Comparison of Contrast Agents for Atherosclerosis Imaging Using Cultured Macrophages: FDG Versus Ultrasmall Superparamagnetic Iron Oxide. J Nucl Med 2013, 54 (6), 999-1004.
  46. Okada H, Ouchi Y, Ogawa M, Futatsubashi M, Saito Y, Yoshikawa E, Terada T, Oboshi Y, Tsukada H, Ueki T, Watanabe M, Yamashita T, Magata Y. Alterations in alpha4beta2 nicotinic receptors in cognitive decline in Alzheimer's aetiopathology. Brain 2013, 136 (Pt 10), 3004-3017.
  47. Takashima N, Kato K, Ogawa M, Magata Y. One-pot sequential reactions for the synthesis of versatile 11C-labeled olefin frameworks. RSC Adv 2013, 3, 21275-21279.
  48. Liu J, Ogawa M, Sakai T, Takashima M, Okazaki S, Magata Y. Differentiation of tumor sensitivity to photodynamic therapy and early evaluation of treatment effect by nuclear medicine techniques. Ann Nucl Med 2013, 27 (7), 669-675.
  49. Kurabe N, Hayasaka T, Ogawa M, Masaki N, Ide Y, Waki M, Nakamura T, Kurachi K, Kahyo T, Shinmura K, Midorikawa Y, Sugiyama Y, Setou M, Sugimura H. Accumulated phosphatidylcholine (16:0/16:1) in human colorectal cancer; possible involvement of LPCAT4. Cancer Sci 2013, 104 10, 1295-1302.
  50. Kojima C, Suehiro T, Watanabe K, Ogawa M, Fukuhara A, Nishisaka E, Harada A, Kono K, Inui T, Magata Y. Doxorubicin-conjugated dendrimer/collagen hybrid gels for metastasis-associated drug delivery systems. Acta Biomater 2013, 9 (3), 5673-5680.
  51. Ogawa M, Nakamura S, Saito Y, Kosugi M, Magata Y. What Can Be Seen by 18F-FDG PET in Atherosclerosis Imaging? The Effect of Foam Cell Formation on 18F-FDG Uptake to Macrophages In Vitro. J Nucl Med 2012, 53 (1), 55-58.
  52. Urano Y, Sakabe M, Kosaka N, Ogawa M, Mitsunaga M, Asanuma D, Kamiya M, Young MR, Nagano T, Choyke PL, Kobayashi H. Rapid cancer detection by topically spraying a gamma-glutamyltranspeptidase-activated fluorescent probe. Sci Transl Med 2011, 3 (110), 110ra119.
  53. Ueda M, Iida Y, Yoneyama T, Kawai T, Ogawa M, Magata Y, Saji H. In vivo relationship between thalamic nicotinic acetylcholine receptor occupancy rates and antiallodynic effects in a rat model of neuropathic pain: persistent agonist binding inhibits the expression of antiallodynic effects. Synapse 2011, 65 (1), 77-83.
  54. Mitsunaga M, Ogawa M, Kosaka N, Rosenblum LT, Choyke PL, Kobayashi H. Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat Med 2011, 17 (12), 1685-1691.
  55. Longmire MR, Ogawa M, Choyke PL, Kobayashi H. Biologically optimized nanosized molecules and particles: more than just size. Bioconjug Chem 2011, 22 (6), 993-1000.
  56. Kojima C, Turkbey B, Ogawa M, Bernardo M, Regino CA, Bryant LH Jr., Choyke PL, Kono K, Kobayashi H. Dendrimer-based MRI contrast agents: the effects of PEGylation on relaxivity and pharmacokinetics. Nanomedicine 2011, 7 (6), 1001-1008.
  57. Kobayashi H, Longmire MR, Ogawa M, Choyke PL. Rational chemical design of the next generation of molecular imaging probes based on physics and biology: mixing modalities, colors and signals. Chem Soc Rev 2011, 40 (9), 4626-4648.
  58. Kobayashi H, Longmire MR, Ogawa M, Choyke PL. Rational chemical design of the next generation of molecular imaging probes based on physics and biology: mixing modalities, colors and signals. Chem Soc Rev 2011, 40 (9), 4626-4648.
  59. Ueda M, Iida Y, Tominaga A, Yoneyama T, Ogawa M, Magata Y, Nishimura H, Kuge Y, Saji H. Nicotinic acetylcholine receptors expressed in the ventralposterolateral thalamic nucleus play an important role in anti-allodynic effects. Br J Pharmacol 2010, 159 (6), 1201-1210.
  60. Regino CA, Ogawa M, Alford R, Wong KJ, Kosaka N, Williams M, Feild BJ, Takahashi M, Choyke PL, Kobayashi H. Two-step synthesis of galactosylated human serum albumin as a targeted optical imaging agent for peritoneal carcinomatosis. J Med Chem 2010, 53 (4), 1579-1586.
  61. Ogawa M, Regino CA, Marcelino B, Williams M, Kosaka N, Bryant LH Jr., Choyke PL, Kobayashi H. New nano-sized biocompatible MR contrast agents based on lysine-dendri-graft macromolecules. Bioconjug Chem 2010, 21 (5), 955-960.
  62. Ogawa M, Nishiyama S, Tsukada H, Hatano K, Fuchigami T, Yamaguchi H, Matsushima Y, Ito K, Magata Y. Synthesis and evaluation of new imaging agent for central nicotinic acetylcholine receptor alpha7 subtype. Nucl Med Biol 2010, 37 (3), 347-355.
  63. Ogawa M, Kosaka N, Regino CA, Mitsunaga M, Choyke PL, Kobayashi H. High sensitivity detection of cancer in vivo using a dual-controlled activation fluorescent imaging probe based on H-dimer formation and pH activation Mol Biosyst 2010, 6 (5), 888-893.
  64. Kosaka N, Ogawa M, Paik DS, Paik CH, Choyke PL, Kobayashi H. Semiquantitative assessment of the microdistribution of fluorescence-labeled monoclonal antibody in small peritoneal disseminations of ovarian cancer. Cancer Sci 2010, 101 (3), 820-825.
  65. Kojima C, Umeda Y, Ogawa M, Harada A, Magata Y, Kono K. X-ray computed tomography contrast agents prepared by seeded growth of gold nanoparticles in PEGylated dendrimer. Nanotechnology 2010, 21 (24), 245104.
  66. Kobayashi H, Longmire MR, Ogawa M, Choyke PL, Kawamoto S. Multiplexed imaging in cancer diagnosis: applications and future advances. Lancet Oncol 2010, 11 (6), 589-95.
  67. Fuchigami T, Yamaguchi H, Ogawa M, Biao L, Nakayama M, Haratake M, Magata Y. Synthesis and biological evaluation of radio-iodinated benzimidazoles as SPECT imaging agents for NR2B subtype of NMDA receptor. Bioorg Med Chem 2010, 18 (21), 7497-7506.
  68. Bumb A, Regino CAS, Perkins MR, Bernardo M, Ogawa M, Fugger L, Choyke PL, Dobson PJ, Brechbiel MW. Preparation and characterization of a magnetic and optical dual-modality molecular probe. Nanotechnology 2010, 21 (17), 209803.
  69. Alford R, Ogawa M, Hassan M, Gandjbakhche AH, Choyke P. L, Kobayashi H. Fluorescence lifetime imaging of activatable target specific molecular probes. Contrast Media Mol Imaging 2010, 5 (1), 1-8.
  70. Turkbey B, Kobayashi H, Ogawa M, Bernardo M, Choyke PL. Imaging of tumor angiogenesis: functional or targeted? AJR Am J Roentgenol 2009, 193 (2), 304-313.
  71. Ogawa M, Tsukada H, Hatano K, Ouchi Y, Saji H, Magata Y. Central in vivo nicotinic acetylcholine receptor imaging agents for positron emission tomography (PET) and single photon emission computed tomography (SPECT). Biol Pharm Bull 2009, 32 (3), 337-340.
  72. Ogawa M, Regino CA, Seidel J, Green MV, Xi W, Williams M, Kosaka N, Choyke PL, Kobayashi H. Dual-modality molecular imaging using antibodies labeled with activatable fluorescence and a radionuclide for specific and quantitative targeted cancer detection. Bioconjug Chem 2009, 20 (11), 2177-2184.
  73. Ogawa M, Regino CA, Choyke PL, Kobayashi H. In vivo target-specific activatable near-infrared optical labeling of humanized monoclonal antibodies. Mol Cancer Ther 2009, 8 (1), 232-239.
  74. Ogawa M, Kosaka N, Longmire MR, Urano Y, Choyke PL, Kobayashi H. Fluorophore-quencher based activatable targeted optical probes for detecting in vivo cancer metastases. Mol Pharm 2009, 6 (2), 386-395.
  75. Ogawa M, Kosaka N, Choyke PL, Kobayashi H. Tumor-specific detection of an optically targeted antibody combined with a quencher-conjugated neutravidin "quencher-chaser": a dual "quench and chase" strategy to improve target to nontarget ratios for molecular imaging of cancer. Bioconjug Chem 2009, 20 (1), 147-154.
  76. Ogawa M, Kosaka N, Choyke PL, Kobayashi H. In vivo molecular imaging of cancer with a quenching near-infrared fluorescent probe using conjugates of monoclonal antibodies and indocyanine green. Cancer Res 2009, 69 (4), 1268-1272.
  77. Ogawa M, Kosaka N, Choyke PL, Kobayashi H. H-type dimer formation of fluorophores: a mechanism for activatable, in vivo optical molecular imaging. ACS Chem Biol 2009, 4 (7), 535-546.
  78. Lucarelli RT, Ogawa M, Kosaka N, Turkbey B, Kobayashi H, Choyke PL. New approaches to lymphatic imaging. Lymphat Res Biol 2009, 7 (4), 205-214.
  79. Longmire M, Kosaka N, Ogawa M, Choyke PL, Kobayashi H. Multicolor in vivo targeted imaging to guide real-time surgery of HER2-positive micrometastases in a two-tumor coincident model of ovarian cancer. Cancer Sci 2009, 100 (6), 1099-1104.
  80. Kosaka N, Ogawa M, Sato N, Choyke PL, Kobayashi H. In vivo real-time, multicolor, quantum dot lymphatic imaging. J Invest Dermatol 2009, 129 (12), 2818-2822.
  81. Kosaka N, Ogawa M, Longmire MR, Choyke PL, Kobayashi H. Multi-targeted multi-color in vivo optical imaging in a model of disseminated peritoneal ovarian cancer. J Biomed Opt 2009, 14 (1), 014023.
  82. Kosaka N, Ogawa M, Choyke PL, Kobayashi H. Clinical implications of near-infrared fluorescence imaging in cancer. Future Oncol 2009, 5 (9), 1501-1511.
  83. Kosaka N, Ogawa M, Choyke PL, Karassina N, Corona C, McDougall M, Lynch DT, Hoyt CC, Levenson RM, Los GV, Kobayashi H. In vivo stable tumor-specific painting in various colors using dehalogenase-based protein-tag fluorescent ligands. Bioconjug Chem 2009, 20 (7), 1367-1374.
  84. Kobayashi H, Ogawa M, Kosaka N, Choyke PL, Urano Y. Multicolor imaging of lymphatic function with two nanomaterials: quantum dot-labeled cancer cells and dendrimer-based optical agents. Nanomedicine (Lond) 2009, 4 (4), 411-419.
  85. Kobayashi H, Ogawa M, Alford R, Choyke PL, Urano Y. New strategies for fluorescent probe design in medical diagnostic imaging. Chem Rev 2009, 110 (5), 2620-2640.
  86. Fuchigami T, Haradahira T, Fujimoto N, Nojiri Y, Mukai T, Yamamoto F, Okauchi T, Maeda J, Suzuki K, Suhara T, Yamaguchi H, Ogawa M, Magata Y, Maeda M. Development of N-[11C]methylamino 4-hydroxy-2(1H)-quinolone derivatives as PET radioligands for the glycine-binding site of NMDA receptors. Bioorg Med Chem 2009, 17 (15), 5665-5675.
  87. Alford R, Simpson HM, Duberman J, Hill GC, Ogawa M, Regino C, Kobayashi H, Choyke PL. Toxicity of organic fluorophores used in molecular imaging: literature review. Mol Imaging 2009, 8 (6), 341-354.
  88. Alford R, Ogawa M, Choyke PL, Kobayashi H. Molecular probes for the in vivo imaging of cancer. Mol Biosyst 2009, 5 (11), 1279-1291.
  89. Ueda M, Iida Y, Kitamura Y, Kawashima H, Ogawa M, Magata Y, Saji H. 5-Iodo-A-85380, a specific ligand for alpha 4 beta 2 nicotinic acetylcholine receptors, prevents glutamate neurotoxicity in rat cortical cultured neurons. Brain Res 2008, 1199, 46-52.
  90. Sekimata K, Hatano K, Ogawa M, Abe J, Magata Y, Biggio G, Serra M, Laquintana V, Denora N, Latrofa A, Trapani G, Liso G, Ito K. Radiosynthesis and in vivo evaluation of N-[11C]methylated imidazopyridineacetamides as PET tracers for peripheral benzodiazepine receptors. Nucl Med Biol 2008, 35 (3), 327-334.
  91. Longmire MR, Ogawa M, Hama Y, Kosaka N, Regino CA, Choyke PL, Kobayashi H. Determination of optimal rhodamine fluorophore for in vivo optical imaging. Bioconjug Chem 2008, 19 (8), 1735-1742.
  92. Ishino S, Mukai T, Kuge Y, Kume N, Ogawa M, Takai N, Kamihashi J, Shiomi M, Minami M, Kita T, Saji H. Targeting of lectinlike oxidized low-density lipoprotein receptor 1 (LOX-1) with 99mTc-labeled anti-LOX-1 antibody: potential agent for imaging of vulnerable plaque. J Nucl Med 2008, 49 (10), 1677-1685.
  93. Fuchigami T, Haradahira T, Fujimoto N, Okauchi T, Maeda J, Suzuki K, Suhara T, Yamamoto F, Sasaki S, Mukai T, Yamaguchi H, Ogawa M, Magata Y, Maeda M. Difference in brain distributions of carbon 11-labeled 4-hydroxy-2(1H)-quinolones as PET radioligands for the glycine-binding site of the NMDA ion channel. Nucl Med Biol 2008, 35 (2), 203-212.
  94. Tajima T, Hatano K, Suzuki M, Ogawa M, Sakiyama Y, Kato T, Endo H, Miura H, Matsubara M, Ito K. Increased binding potential of [(11)C]raclopride during unilateral continuous microinjection of nicotine in rat striatum observed by positron emission tomography. Synapse 2007, 61 (12), 943-950.
  95. Ishino S, Mukai T, Kume N, Asano D, Ogawa M, Kuge Y, Minami M, Kita T, Shiomi M, Saji H. Lectin-like oxidized LDL receptor-1 (LOX-1) expression is associated with atherosclerotic plaque instability--analysis in hypercholesterolemic rabbits. Atherosclerosis 2007, 195 (1), 48-56.
  96. Ogawa M, Tatsumi R, Fujio M, Katayama J, Magata Y. Synthesis and evaluation of [125I]I-TSA as a brain nicotinic acetylcholine receptor alpha7 subtype imaging agent. Nucl Med Biol 2006, 33 (3), 311-316.
  97. Ogawa M, Magata Y, Kato T, Hatano K, Ishino S, Mukai T, Shiomi M, Ito K, Saji H. Application of 18F-FDG PET for monitoring the therapeutic effect of antiinflammatory drugs on stabilization of vulnerable atherosclerotic plaques. J Nucl Med 2006, 47 (11), 1845-1850.
  98. Ogawa M, Iida Y, Nakagawa M, Kuge Y, Kawashima H, Tominaga A, Ueda M, Magata Y, Saji H. Change of central cholinergic receptors following lesions of nucleus basalis magnocellularis in rats: search for an imaging index suitable for the early detection of Alzheimer's disease. Nucl Med Biol 2006, 33 (2), 249-254.
  99. Hosokawa R, Kambara N, Ohba M, Mukai T, Ogawa M, Motomura H, Kume N, Saji H, Kita T, Nohara R. A catheter-based intravascular radiation detector of vulnerable plaques. J Nucl Med 2006, 47 (5), 863-867.
  100. Ogawa M, Watabe H, Teramoto N, Miyake Y, Hayashi T, Iida H, Murata T, Magata Y. Understanding of cerebral energy metabolism by dynamic living brain slice imaging system with [18F]FDG. Neurosci Res 2005, 52 (4), 357-361.
  101. Ueda M, Iida Y, Mukai T, Mamede M, Ishizu K, Ogawa M, Magata Y, Konishi J, Saji H. 5-[123I]Iodo-A-85380: assessment of pharmacological safety, radiation dosimetry and SPECT imaging of brain nicotinic receptors in healthy human subjects. Ann Nucl Med 2004, 18 (4), 337-344.
  102. Ohnishi T, Hayashi T, Okabe S, Nonaka I, Matsuda H, Iida H, Imabayashi E, Watabe H, Miyake Y, Ogawa M, Teramoto N, Ohta Y, Ejima N, Sawada T, Ugawa Y. Endogenous dopamine release induced by repetitive transcranial magnetic stimulation over the primary motor cortex: an [11C]raclopride positron emission tomography study in anesthetized macaque monkeys. Biol Psychiatry 2004, 55 (5), 484-489.
  103. Ogawa M, Ishino S, Mukai T, Asano D, Teramoto N, Watabe H, Kudomi N, Shiomi M, Magata Y, Iida H, Saji H. (18)F-FDG accumulation in atherosclerotic plaques: immunohistochemical and PET imaging study. J Nucl Med 2004, 45 (7), 1245-1250.
  104. Ogawa M, Ishino S, Mukai T, Asano D, Teramoto N, Watabe H, Kudomi N, Shiomi M, Magata Y, Iida H, Saji H. Imaging of Vulnerable Atherosclerotic Plaque with [18F]FDG-PET: An Animal Atherosclerosis Model Study. 2004, pp. 266-268.
  105. Mukai T, Nohara R, Ogawa M, Ishino S, Kambara N, Kataoka K, Kanoi T, Saito K, Motomura H, Konishi J, Saji H. A catheter-based radiation detector for endovascular detection of atheromatous plaques. Eur J Nucl Med Mol Imaging 2004, 31 (9), 1299-1303.
  106. Iida Y, Ogawa M, Ueda M, Tominaga A, Kawashima H, Magata Y, Nishiyama S, Tsukada H, Mukai T, Saji H. Evaluation of 5-(11)C-methyl-A-85380 as an imaging agent for PET investigations of brain nicotinic acetylcholine receptors. J Nucl Med 2004, 45 (5), 878-884.
  107. Takahata K, Shimazu S, Yoneda F, Ogawa M, Iida Y, Saji H. Effects of monoamine oxidase inhibitors on the diethyldithiocarbamate-induced enhancement of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in C57BL/6 mice. J Neural Transm 2003, 110 (8), 859-869.
  108. Saji H, Iida Y, Kawashima H, Ogawa M, Kitamura Y, Mukai T, Shimazu S, Yoneda F. In vivo imaging of brain dopaminergic neurotransmission system in small animals with high-resolution single photon emission computed tomography. Anal Sci 2003, 19 (1), 67-71.
  109. Ogawa M, Hatano K, Oishi S, Kawasumi Y, Fujii N, Kawaguchi M, Doi R, Imamura M, Yamamoto M, Ajito K, Mukai T, Saji H, Ito K. Direct electrophilic radiofluorination of a cyclic RGD peptide for in vivo alpha(v)beta3 integrin related tumor imaging. Nucl Med Biol 2003, 30 (1), 1-9.
  110. Ogawa M, Hatano K, Kawasumi Y, Ishiwata K, Kawamura K, Ozaki S, Ito K. Synthesis and evaluation of 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-[(11)C]ethyl- 1,3-dihydro-2H-benzimidazol-2-one as a brain ORL1 receptor imaging agent for positron emission tomography. Nucl Med Biol 2003, 30 (1), 51-59.
  111. Magata Y, Temma T, Iida H, Ogawa M, Mukai T, Iida Y, Morimoto T, Konishi J, Saji H. Development of injectable O-15 oxygen and estimation of rat OEF. J Cereb Blood Flow Metab 2003, 23 (6), 671-676.
  112. Kudomi N, Eunjoo C, Yamamoto S, Watabe H, Kyeong Min K, Shidahara M, Ogawa M, Teramoto N, Sakamoto E, Iida H. Development of a GSO detector assembly for a continuous blood sampling system. IEEE Trans Nucl Sci 2003, 50 (1), 70-73.
  113. Saji H, Ogawa M, Ueda M, Iida Y, Magata Y, Tominaga A, Kawashima H, Kitamura Y, Nakagawa M, Kiyono Y, Mukai T. Evaluation of radioiodinated 5-iodo-3-(2(S)-azetidinylmethoxy)pyridine as a ligand for SPECT investigations of brain nicotinic acetylcholine receptors. Ann Nucl Med 2002, 16 (3), 189-200.
  114. Kiyono Y, Kanegawa N, Kawashima H, Iida Y, Kinoshita T, Tamaki N, Nishimura H, Ogawa M, Saji H. Age-related changes of myocardial norepinephrine transporter density in rats: implications for differential cardiac accumulation of MIBG in aging. Nucl Med Biol 2002, 29 (6), 679-684.
  115. Kiyono Y, Iida Y, Kawashima H, Ogawa M, Tamaki N, Nishimura H, Saji H. Norepinephrine transporter density as a causative factor in alterations in MIBG myocardial uptake in NIDDM model rats. Eur J Nucl Med Mol Imaging 2002, 29 (8), 999-1005.
  116. Ogawa M, Hatano K, Kawasumi Y, Wichmann J, Ito K. Synthesis and in vivo evaluation of [11C]methyl-Ro 64-6198 as an ORL1 receptor imaging agent. Nucl Med Biol 2001, 28 (8), 941-947.
  117. Ogawa M, Hatano K, Kawasumi Y, Ishiwata K, Kawamura K, Ozaki S, Ito K. Synthesis of 11C-labeled ORL1 imaging agents, with [11C]CH3I and [11C]C2H5I. J Labelled Compd Radpharm 2001, 44, S265-S267.
  118. Hatano K, Suzuki M, Ogawa M, Kawasumi Y, Kato T, Ito K, Kamei K. Direct and indirect synthesis of fluorine-18 labeled butyrophenones as a1-adrenoceptor ligands. J Labelled Compd Radpharm 2001, 44, S898-S900.

Japanese Reviews

  1. 小川美香子、生体分子イメージングにおける電離・非電離放射線の効果的な使い方、放射線生物研究、Vol.52 (2017)、No.3、254-262
  2. 小川美香子、DDS先端技術の製剤への応用開発（第9章1節）In vivo イメージング法によるDDS評価、443-449、2017
  3. 小川美香子、生体蛍光イメージングの基礎とactivatable probe 総論、臨床画像、32 (2)、233-237、2016
  4. 小川美香子、DDS研究のための最新機器: ハンドヘルドの近赤外蛍光カメラ、Drug Delivery System、30 (2)、55-58、2015
  5. 小川美香子、動脈硬化不安定プラークの光イメージング、光アライアンス、24 (9)、25-28、2013
  6. 小川美香子、ニコチン性アセチルコリン受容体イメージング、PET Journal、23、28-30、2013
  7. 小川美香子、アクチベータブル近赤外蛍光プローブの創製による蛍光がんイメージング、実験医学、30 (7)、1087-1093、2012
  8. 小川美香子、小林久隆、蛍光プローブによる微小癌細胞の生体イメージング、Surgery Frontier、18 (1)、19-28、2011
  9. 児島千恵、小川美香子、PEG化デンドリマーを用いたX線CT造影剤の開発とその応用、バイオマテリアル、29、88-94、2011
  10. 小川 美香子、小林 久隆蛍光複合プローブの課題、BIO Clinica、25 (9)、24-29、2010
  11. 小川美香子、小林久隆、腫瘍の光イメージング、JSMI report: 3 (1)、8-13、2010
  12. 小川美香子、腫瘍の光イメージング、PET journal、12、24-26、2010
  13. 『心・血管病の分子イメージング』 (Jagat Narula・今泉 勉 監修、田原 宣広 編集)、第4章分子イメージングの基礎 4.FDG、小川美香子、2010、永井書店 2010
  14. 同、第7章分子イメージングによる薬物治療の評価 3.プロブコール、小川美香子、2010、永井書店 2010
  15. 小川美香子、アミロイドβプラークのイメージング、PET通信、49、12-15、2004
  16. 小川美香子、特集PET～ここまでわかる画像診断～ 1. PETの基礎．医薬ジャーナル、40、75-78、2004
  17. 小川美香子、トピックス [18F]FLTは次世代腫瘍診断薬剤となり得るか？ ファルマシア、40、60-61、2004
  18. 小川美香子、アミロイドβプラークの核医学イメージング　RADIOISOTOPES、52、315-317、2003